Last reviewed · How we verify
NCT05017805
COVID-19 Vaccines in Patients With Chronic Liver Disease
NA trial testing COVID-19 Vaccines in Liver Disease Chronic in 300 participants. Status unknown.
15 August 2024
Quick facts
| Lead sponsor | Beijing 302 Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 300 |
| Start date | 15 August 2021 |
| Primary completion | 15 August 2024 |
| Estimated completion | 15 August 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- COVID-19 Vaccines — full drug profile →
Conditions studied
- Liver Disease Chronic — all drugs for Liver Disease Chronic →
Sponsor
Beijing 302 Hospital
Who can join
18 and older, any sex, with Liver Disease Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused pandemic since outbreak in 2020.Patients with chronic liver disease (CLD) are at higher risk of mortality and morbidity due to COVID-19. Despite there is a large number of clinical trials of COVID-19 vaccines, only a few participants with chronic liver diseases were included.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Chronic Liver Disease
Mao Y, Gao L, Li Y, Wang F. · · 2023
Verify or expand the search:
- PubMed search for NCT05017805
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of COVID-19 Vaccines
Trials testing the same drug.
- NCT05028257 — Allergy and COVID-19 Vaccines · Phase 3 · completed
- NCT04981405 — Real-world Evidence of COVID-19 Vaccines Effectiveness · terminated
- NCT05228912 — Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries. · completed
- NCT04706143 — Immunologic Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians · unknown
Other recruiting trials for Liver Disease Chronic
Currently open trials in the same condition.
- NCT07487623 — Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chron · NA · recruiting
- NCT05205954 — HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease · NA · recruiting
Other Beijing 302 Hospital trials
Trials by the same sponsor.
- NCT07514832 — VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial · Phase 2 · recruiting
- NCT07297173 — Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia · Phase 1 · recruiting
- NCT06556862 — Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor · Phase 2 · not yet recruiting
- NCT07106658 — TEAS for Variceal Bleeding Endoscopy in Cirrhosis · NA · completed
- NCT06926647 — A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05017805 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing 302 Hospital
- Last refreshed: 22 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05017805.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing